potassium voltage-gated channel subfamily E regulatory subunit 3
RGD ID:
621384
Description:
Exhibits ion channel binding activity and potassium channel regulator activity. Involved in negative regulation of delayed rectifier potassium channel activity and positive regulation of voltage-gated calcium channel activity. Localizes to plasma membrane. Colocalizes with voltage-gated potassium channel complex. Human ortholog(s) of this gene implicated in Brugada syndrome 6 and hypokalemic periodic paralysis. Orthologous to human KCNE3 (potassium voltage-gated channel subfamily E regulatory subunit 3); INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; all-trans-retinoic acid; ammonium chloride.
[Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of KCNE3 mRNA
[Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of KCNE3 mRNA
6-cyano-4-N-ethylsulfonyl-N-methylamino-3-hydroxy-2, 2-dimethylchromane inhibits the reaction [[KCNQ1 protein binds to KCNE3 protein] which affects the transport of Potassium]
[Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of KCNE3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of KCNE3 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of KCNE3 mRNA
[Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of KCNE3 mRNA
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin